Tegaserod

• UNSPSC Description:

  Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].

• Target Antigen:

  5-HT Receptor; Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;GPCR/G Protein;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/tegaserod.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(NC=C2/C=N/NC(NCCCCC)=N)C2=C1

• Molecular Weight:

  301.39

• References & Citations:

  [1]Wei Liu, et al. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2020 Feb 21;39(1):38.|[2]M D Crowell, et al. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol Motil. 2005 Oct;17(5):738-43.|[3]D T Beattie, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Launched

• CAS Number:

  145158-71-0